This article was downloaded by:

On: 27 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-

41 Mortimer Street, London W1T 3JH, UK



### Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information: http://www.informaworld.com/smpp/title~content=t713597286

# A<sub>1</sub> and A<sub>2</sub> Adenosine Receptors Involvement in Controlling Purine and Acetylcholine Release From Rat Hippocampal Slices

P. Di Iorio<sup>a</sup>; P. Ballerini<sup>a</sup>; R. Ciccarelli<sup>a</sup>; M. Di Muzio<sup>a</sup>; U. Traversa<sup>b</sup>; F. Caciagli<sup>a</sup>
<sup>a</sup> Institute of Neuroscience, Chair of Pharmacology, University of Chieti, Chieti, Italy <sup>b</sup> Institute of Pharmacology and Pharmacognosy, Chair of Molecular Pharmacology, University of Trieste, Trieste, Italy

To cite this Article Iorio, P. Di , Ballerini, P. , Ciccarelli, R. , Muzio, M. Di , Traversa, U. and Caciagli, F.(1991) 'A $_{\scriptscriptstyle 1}$  and A $_{\scriptscriptstyle 2}$  Adenosine Receptors Involvement in Controlling Purine and Acetylcholine Release From Rat Hippocampal Slices', Nucleosides, Nucleotides and Nucleic Acids, 10: 5, 1237 - 1238

To link to this Article: DOI: 10.1080/07328319108047290 URL: http://dx.doi.org/10.1080/07328319108047290

#### PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

## A1 AND A2 ADENOSINE RECEPTORS INVOLVEMENT IN CONTROLLING PURINE AND ACETYLCHOLINE RELEASE FROM RAT HIPPOCAMPAL SLICES.

Di lorio P., Ballerini P., Ciccarelli R., Di Muzio M. §Traversa U. and Caciagli F.\*

Institute of Neuroscience, Chair of Pharmacology, University of Chieti,
Via dei Vestini 31, Chieti, Italy.

§Institute of Pharmacology and Pharmacognosy, Chair of Molecular Pharmacology, University of Trieste, Via A. Valerio 32, Trieste, Italy.

<u>Abstract</u>: The different role of presynaptic  $A_1$  and  $A_2$  adenosine receptor subtypes on a possible autoregulation of endogenous purine outflow as well as on the ACh release, simultaneously assayed, was evaluated in rat hippocampal slices, at rest and under a field electrical stimulation.

The biochemical and physiological mechanisms that control purine secretion are not sufficiently known, even if the existence of an autoregulation of purine release, as well as it was widely described for other neurotransmitter systems, was more than once suggested.

In this study, the possible autoregulation of endogenous purine release and their influence on ACh one were investigated in slices of rat hippocampus, at rest and under field electrical stimulation (30 mA/cm $^2$ , 5 msec for 5 min at 5 Hz). Fractional release of labelled purines and ACh, derived, at the same time, from slices incubated for 30 min with  $^3$ H-adenosine and  $^{14}$ C-choline chloride and cosidered as tracers of their released total amounts, were simultaneously assayed.

The involvement of  $A_1$  sites in the regulation of  $^3H$ -purine and  $^{14}C$ -ACh releases was evaluated by using 8-cyclopentyl-1,3-dipropylxanthine (DPCPX) (from 1 to 200nM), a selective  $A_1$  receptor antagonist. The drug did not affect basal releases of both  $^3H$ -purine and  $^{14}C$ -ACh, thus suggesting that they did not seem to be subjected to an inhibiting  $A_1$ -mediated regulation. On the contrary, DPCPX progressively increased the electrically evoked  $^3H$ -purine outflow, beginning from the dose of 10nM. The simultaneous evoked  $^{14}C$ -ACh release, instead, was differently

1238 DI IORIO ET AL.

affected: at 10nM it was reduced, while it was dose-dependently increased at higher doses. These results confirmed the well known inhibitory control that adenosine exerted on transmitter release, via  $A_1$  receptor sites, and they supported the hypothesis of an  $A_1$ -mediated inhibitory autoregulation of purine release.

Considering the observed effect of DPCPX on its whole, it seemed reasonable to suppose that the possible  $A_1$ -mediated control on ACh and purine releases became to be effective only when remarkable amounts of purine were released, as well as it occurred under electrical stimulation. Furthermore, since different concentrations of DPCPX needed to counteract the adenosine control on purine and ACh releases respectively, it was possible to hypothesize that the inhibitory purinergic autoreceptor and the adenosine receptor controlling the evoked release of ACh could belong to different subclasses of  $A_1$  receptor with a different sensitivity to endogenous adenosine.

PD115,199 (0.5-1µM), an antagonist with a high potency on Ap receptor<sup>1</sup>, significantly reduced basal <sup>3</sup>H-purine outflow more than that observed for the evoked one. Only the highest dose parallely affected the  $^{14}C$ -ACh release too. These findings were suggestive for an  $A_2$ mediated positive "tonic" control on the basal releases of transmitters as ACh and cotransmitters as purines. The involvement of  $A_{\sigma}$  receptor in an autoregulatory mechanism of purine release was confirmed by the effect of NECA (50-100nM), a mixed  $\Lambda_1/\Lambda_2$  agonist, administered alone or in combination with DPCPX, 50nM NECA produced only an inhibitory threshold effect, whereas 100nM NECA significantly inhibited both  $^3\mathrm{H-}$ purine and <sup>14</sup>C-ACh outflows. These effects were consistent with a prevalent activation of A<sub>1</sub> receptor. Conversely, the stimulating effect on purine and ACh releases, due to the simultaneous administration of NECA and DPCPX aimed at obtaining a selective activation of Ap receptors sites, confirmed that they were positively involved in the adenosine-mediated control of purine and transmitter releases, as it was more than once suggested<sup>2,3</sup>.

#### REFERENCES

1-Bruns,R.F., Fergus,J.H., Badger,E.W., Bristol,J.A., Santay,L.A., Hays, S.J. (1987) Naunyn Schmiedeberg's Arch. Pharmacol. 335,64-69.

2-Spignoli,G., Pedata,F., Pepeu G. (1984) Eur. J. Pharmacol. 97,341-342.

3-Dolphin,A.C. and Prestwich S.A. (1985) Nature 316,148-150.